MICROLEARNING In for the Long Haul: Identifying and Managing Residual MDD Symptoms – Module 2

Residual symptoms—also known as symptoms characteristic of incomplete response to treatment, or as partial remission—are experienced by most patients treated for major depressive disorder (MDD). These lingering symptoms include fatigue, anxiety, depressed mood, somatic symptoms, reduced sexual desire, cognitive issues, sleep problems, and anhedonia, among others. Even patients with relatively low levels of residual symptoms can experience significant impairment, as well as a strain on their social roles. They are likely to use healthcare services more frequently, as well. Unresolved residual symptoms have the potential to contribute to recurrent or chronic depression and even put the affected patient at higher risk for suicide. 

After participating in this education, learners will be able to:

• Identify evidence-based pharmacologic treatment options that are available to treat

residual MDD symptoms.

• Select appropriate treatment for specific residual MDD symptoms in response to

provided case simulations

CONTENT REVIEWER

Una Hopkins, DNP

PLANNERS

Núria Waddington Negrão, PhD  

Sapana Panday, MPH 

CREDIT DESIGNATIONS 

Albert Einstein College of Medicine-Montefiore Medical Center designates this live activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Albert Einstein College of Medicine-Montefiore Medical Center designates this activity for 0.25 nursing contact hours.  Nurses should claim only credit commensurate with the extent of their participation in the activity 

Albert Einstein College of Medicine-Montefiore Medical Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

This activity is supported by an educational grant from Takeda Pharmaceuticals USA, Inc. 

The "Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships" at Albert Einstein College of Medicine-Montefiore Medical Center mandates that all individuals, including faculty, who have control over content in CME/CE activities, must disclose any relevant financial relationships with ineligible companies*, or the absence of such relationships, from the past 24 months to the audience. Any individual in control of content who refuses to disclose, or their disclosed relationships prove to create a conflict of interest will be recused. 

All financial relationships of individual(s) in a position to control the content of this CME/CE activity has been identified and mitigated prior to this educational activity.  

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.  

Andrew Penn, MS, NP, PMHNP-BC 
Consultant: Alkermes plc, Luciem, Osmind Inc., Otsuka Pharmaceutical Co., Ltd., Tactogen 
Research Grants: Filament Health Corp. 
Stock ownership: Osmind Inc., Tactogen 

Catherine Judd, DMSc, PA-C, CAQ Psychiatry, DFAAPA does not have any financial relationships or relationships to products or devices with ineligible companies 

Núria Waddington Negrão, PhD does not have any financial relationships or relationships to products or devices with ineligible companies 

Sapana Panday, MPH does not have any financial relationships or relationships to products or devices with ineligible companies 

Una Hopkins, DNP does not have any financial relationships or relationships to products or devices with ineligible companies